AlphAIAlphAI — Financial news for AI agents
rttnews.comNOV 42 min read$ZBH

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

Original reporting
rttnews.com
Published Nov 4, 2026, 12:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook — source image
Source · rttnews.com
Decision brief

The 30-second read

$ZBHBullishHigh
01

Why it matters

The earnings miss on profit is offset by an upgraded FY26 EPS and revenue outlook, creating a mixed signal for traders.

02

Market read

First‑report earnings and guidance update for ZBH, a mid‑cap healthcare stock, with potential short‑term trading impact.

03

What to watch

Potential cost pressures or competitive dynamics not disclosed in the release.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Zimmer Biomet is a leading orthopedic implant and surgical device maker. The Q3 results were released on Nov 4 2026.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet reported lower Q3 profit but raised its FY26 earnings per share and revenue outlook.

Expected impact

likely slight upward pressure as investors price in higher FY guidance despite weaker quarter profit

Evidence & confidence

The earnings beat on guidance is a fresh, material data point for a mid‑cap medical device company.

Market effects

Sector

May lift sentiment for the broader medical device sector as guidance upgrades suggest resilient demand.

Regional

U.S. healthcare stocks could see modest gains in early trading.

Global

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

What could challenge this read

Profit decline could signal underlying demand weakness, making the guidance raise insufficient for a rally.

Key entities

  • company
    Zimmer Biomet Holdings, Inc.

    Medical device manufacturer reporting Q3 results.

Read at source← All news

StoryZimmer Biomet posts Q3 2026 results and lifts full‑year outlook

Also covered by

5 outlets

Related articles

NOV 4
$ZBHHighAI 8/10

Zimmer Biomet beats Q3 estimates, raises guidance

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

investing.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 2026 revenue of $2.06B, beating estimates by 1.1% and growing 3.1% YoY. Adjusted EPS was $1.90, a 1% beat. Management raised full-year adjusted EPS guidance to $8.55. Operating margin declined to 14.9%, while free cash flow margin increased to 18.1%. Constant currency revenue grew 3.7% YoY, down from 8.6% last quarter.

finance.yahoo.com1 min
NOV 4
$ZBHHighAI 8/10

Zimmer: Q3 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

finance.yahoo.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Sales Rise 3.1%; Raises 2026 Growth Guidance

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.

tradingview.com1 min